Loading...
XNAS
ACRS
Market cap316mUSD
Dec 05, Last price  
2.92USD
1D
-2.99%
1Q
39.05%
Jan 2017
-89.24%
IPO
-73.57%
Name

Aclaris Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ACRS chart
P/E
—
P/S
16.90
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.34%
Rev. gr., 5y
34.66%
Revenues
19m
-40.09%
00001,683,00010,091,0004,227,0006,482,0006,761,00029,752,00031,249,00018,720,000
Net income
-132m
L+49.26%
-5,236,000-8,517,000-20,563,000-48,079,000-68,523,000-132,738,000-142,850,000-51,154,000-114,281,000-88,662,000-88,481,000-132,065,000
CFO
-20m
L-74.37%
-4,920,000-7,636,000-20,369,000-34,603,000-54,663,000-100,811,000-96,445,000-38,633,000-52,134,000-67,567,000-78,325,000-20,075,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
URL
https://www.aclaristx.com/
IPO date
Oct 07, 2015
Employees
100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT